Cog-Angio

Impact of anti-angiogenic treatments on quality of life and cognitive functions of metastatic renal cell carcinoma adult patients.

Coordinator: F. Joly

Background: Recent therapeutic advances have led to the development of effective angiogenesis inhibitors for the treatment of metastatic kidney cancer. These therapies have revolutionised patient treatment and become the new treatment of reference in few years. New adverse effects have been observed but their impact on quality of life has not yet been well evaluated. These effects likely include fatigue and cognitive impairment. This is the first study to assess the impact of angiogenic inhibitors on cognitive function.

Objectives: Evaluate the incidence and evolution of fatigue, memory impairment and attention deficits caused by angiogenesis inhibitors in metastatic kidney cancer patients.

Study methodology: This is a non-randomised, longitudinal, multicenter, descriptive observational pilot study on patients receiving an angiogenesis inhibitor treatment for metastatic kidney cancer. The recruitment phase is closed and 75 patients have been enrolled.

Current study status: Inclusion phase closed. Study under way.

Collaboration: Four participating centers

Sponsor: Roche

Publications:

Denouel A, Heutte N, Escudier B, Kurtz JE, Santos MD, Longato N, Desrues L, Dauchy S, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Noal S, Joly F. Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies. Clin Genitourin Cancer.2018 May 21. pii:S1558-7673(18)30286-6. doi: 10.1016/j.clgc.2018.05.013. [Epub ahead of print] PubMed PMID: 30007862

Joly, F., Heutte, N., Duclos, B., Noal, S., Léger, I., Dauchy, S., Longato, N., Desrues, L., Houédé, N., Lange, M., Sevin, E., Rieux, C., Clarisse, B., Castel, H., Escudier, B. (2016). Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer. European Urology Focus, 2(6), 642-649